According to the Xingqi Pharmaceutical announcement, the company received the “Drug Clinical Trial Approval Notice” for the SQ-25012 injection issued by the State Drug Administration and agreed to carry out clinical trials for the treatment of thyroid eye disease. This drug is a recombinant humanized IgG1 trispecific antibody. It is a class 1 innovative drug for therapeutic biological products. The company has completed pharmaceutical and non-clinical pharmacological toxicology studies, and the results show that it has good safety and clinical development value. As of the date of disclosure of the announcement, no drug of the same type has been approved for marketing.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.